/
Musculoskeletal
Muscular Atrophy, Spinal
3
Pipeline Programs↗
10
Active Trials↗
2
Companies Involved↗
Muscular Atrophy, Spinal is an early-stage landscape with 3 programs across 2 companies. The most active players are Biogen, Roche. 2 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 11
Phase 2
No programs
Phase 32
Approved
No programs
Analysis
Modality Breakdown
67%
RNA therapy
2 of 3 classified programs — the dominant modality here.
RNA therapy leads; the ring shows all 3 classified programs, each share of the total. Modality classified for 100% of 3 pipeline programs.
Analysis
Trial Status
12
clinical trials
Active, not recruiting5 · 42%
Recruiting5 · 42%
Completed2 · 17%
Clinical Trials
Trial Activity
12 trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)